Multi-indication study-story waitlist

Clinical study stories with citations — for competitive intelligence, medical affairs, and BD.

Clinflare turns registry records and protocol/SAP PDFs into structured study pages — not another landscape database. Identity, Design, SoA, Endpoints, and Results, with every claim cited. Join the waitlist for early access and indication digests starting with the wave-1 indications below — contested franchises where briefing load is highest.

Join the waitlist Why we’re not a landscape tool →

Why Clinflare

Full study story, one page

Stop rebuilding binders from ClinicalTrials.gov and PDFs. Get a structured view of Identity, Design, Schedule of Assessments (SoA), Endpoints (primary + key secondary with definitions and timing), and Results for the studies that matter to your brief.

Citations and provenance built in

Every extracted field points back to source (file + page/section). Low-confidence stays flagged; missing fields say “Not in sources” — never silently filled. Built for people who cannot paste an unverifiable chatbot paragraph into a leadership deck.

Indication + product depth, not landscape spray

Hubs and digests by the indications and products you care about — study-story depth for CI, medical affairs, and BD seats — without buying a modality-wide enterprise landscape ontology.

Indications we start with (wave-1)

We publish indication and product hubs where protocol density and buyer demand are highest. Starting list (CoS-approved):

  1. Obesity / incretin & next-gen metabolic
  2. ATTR amyloidosis (CM + PN) — one spoke among several, not the sole focus
  3. MASH / metabolic liver
  4. HER2+ / HER2-low breast (ADC & sequencing)
  5. NSCLC — ADC, IO, and targeted

Expansion past these five waits on Search Console demand and waitlist interest tags — not a coverage race.

Depth-proof (honest)

Pricing teaser

When seats open, we expect simple team pricing — roughly Solo $49 / Team $99 / Team+ $149+ per month (hypothesis; final pricing confirmed at launch). Floor stays at $49. Waitlist members hear first. No race-to-bottom seats.

Solo $49/mo
Team $99/mo
Team+ $149+/mo

Hypothesis only — not a binding offer.

What you get on the waitlist

  • Early access to Clinflare’s study-story product as it opens
  • Indication digests — curated signal on trial updates, protocol/SAP drops, and readout context for the tags you select (cadence announced to waitlist; not a promise of live product fidelity)
  • Shape what we ship first — multi-select indication interest (below) so we prioritize extracts where demand is real
  • Founding pricing notice when Solo / Team seats open

Indication interest (preview)

The Google Form (linked from the CTA below) will collect these as multi-select checkboxes, plus your role. This section is a visual preview of what you’ll select.

Which indications should we prioritize for you? (select all that apply)

Role (on the form — single-select or free text): CI / Medical affairs / BD / Other

How this differs from Beacon / landscape tools

Beacon-class tools (e.g. Beacon Intelligence / Hanson Wade) excel at scientist-curated enterprise landscapes — drugs, trials, companies, deals — with deep modality and TA ontologies.

Clinflare is different by design:

Landscape tools Clinflare (study stories)
Breadth across modalities / TAs Depth on cited clinical study stories
Expert-curated landscape objects Registry + protocol/SAP extract with citations
Enterprise research / pipeline seats Individuals and small CI / Med Affairs / BD teams

If you need exhaustive deal and modality ontologies, keep your landscape vendor. If you need a cited study page for tomorrow’s brief, join this waitlist.

FAQ

Who is this for?
Competitive intelligence, medical affairs / evidence, and BD people at pharma and biotech — individuals and small teams who live in study briefs. Not generalist “all of oncology” landscape buyers.
Is Clinflare a Beacon competitor?
Not as a landscape database. Beacon sells curated enterprise landscape intelligence. Clinflare focuses on clinical study stories — structured pages (Identity, Design, SoA, Endpoints, Results) with provenance. Many teams may use both for different jobs.
Can I get a live demo / gold sample pages now?
Not yet. The product is not demo-polished. The waitlist is for early access and indication digests while we lock study schema and extracts. An ATTRibute-CM page exists as a depth-proof example of shape, not finished library collateral. We will not oversell fidelity.
Which indications?
We start with a short confirmed list: obesity / incretin metabolic, ATTR (CM + PN), MASH / metabolic liver, HER2+ / HER2-low breast ADC, and NSCLC (ADC / IO / targeted). ATTR is included; it is not the only focus. We do not expand past these five until Search Console and waitlist tags justify it. AL amyloidosis is out of scope for ATTR pages.
Where does the data come from?
Public registry snapshots plus protocol/SAP (and related) PDF extract into Identity, Design, SoA, Endpoints, and Results — each value cited, low-confidence flagged, or marked “Not in sources.” We do not claim scientist hand-curation of every landscape object.
What happens after I join?
Confirm email → waitlist confirmation → digest / early-access notices for your selected indications as ready. No spam; unsubscribe anytime.

Join the waitlist

Early access and indication digests for the tags you select. Work email preferred.

Waitlist form wiring in progress — check back shortly.

Join the waitlist

Work email preferred. We’ll only send early-access and digest updates for the indications you select — no demo theater.

We use your email for waitlist and product updates related to Clinflare. No sale of contact data.